TTD Drug ID: DAP000006

Drug Information
Name	Sorafenib
Synonyms	BAY-54-9085; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; BAY-43-0006; Sorafenib [INN]; NCGC00167488-01; CID216239; D08524; CHEBI:50924; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Kinome_766; Bio-0100; sorafenibum; BAY 439006; Sorafenib; AC-1674; BAY 54-9085 (tosylate salt); LS-187788; DB00398; ZINC01493878; 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-; LS-186067; MolPort-003-850-270; Nexavar; DB07438; BAY-43-9006; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; NSC-724772; K00597a; AB1004622; BRD-K23984367-001-01-8; STK627350; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; I06-0856; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; BAY 43-9006 (free base); CHEBI:47228; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; nchembio.117-comp17; CHEMBL1336; N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; BAX; EN002709; AC1L50CF; Sorafenib (INN); 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-; NSC747971; LS-187021; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; UNII-9ZOQ3TZI87; BAY 43-9006; BAY43-9006; 284461-73-0; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
Trade Name	Nexavar
Company	Bayer AG/Onyx Pharmaceuticals
Indication	Advanced renal cell carcinoma [ICD9: 189   ICD10: C64]			Launched    [1]
	Hepatocellular carcinoma, NSCLC, melanoma [ICD9: 155, 162, 172   ICD10: C22.0, C33, C34, C43]			Phase III    [1]
	Myelodyspalstic syndrome, AML, head & neck cancer, breast, colon, ovarian, pancreatic cancer [ICD9: 140-149, 140-229, 157, 183, 205.0   ICD10: C00-C96, C07-C14, C25, C32, C33, C56, C92.0]			Phase II    [1]
Structure	Click to save drug structure in 3D MOL format Click to save drug structure in 2D MOL format
InChI	1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6 -14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,2 6,30)(H2,28,29,31)
InChIKey	MLDQJTXFUGDVEO-UHFFFAOYSA-N
Canonical SMILES	CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Therapeutic Class	Antineoplastic Agents
CAS Number	CAS 284461-73-0
Formula	C21H16ClF3N4O3
PubChem Compound ID	CID 216239.
PubChem Substance ID	SID 789424.
ChEBI	50924;
SuperDrug ATC ID	L01XE05
	L01XE05
Target	B-Raf proto-oncogene serine/threonine-protein kinase			Inhibitor	[2][3][4]
	B-Raf proto-oncogene serine/threonine-protein kinase			Multitarget	[2][3][4]
	Proto-oncogene tyrosine-protein kinase receptor ret			Inhibitor	[2][3][4]
	Proto-oncogene tyrosine-protein kinase receptor ret			Multitarget	[2][3][4]
	Vascular endothelial growth factor receptor			Inhibitor	[2][3][4]
	Vascular endothelial growth factor receptor			Multitarget	[2][3][4]
Ref 1	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. To Reference
Ref 2	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 3	Pituitary tumors. Curr Treat Options Neurol. 2009 Jul;11(4):287-96. To Reference
Ref 4	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28. To Reference

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.